Denali Therapeutics Management
Management criteria checks 3/4
Denali Therapeutics' CEO is Ryan Watts, appointed in Aug 2015, has a tenure of 9.17 years. total yearly compensation is $7.88M, comprised of 8.5% salary and 91.5% bonuses, including company stock and options. directly owns 1.57% of the company’s shares, worth R$350.76M. The average tenure of the management team and the board of directors is 5.8 years and 8 years respectively.
Key information
Ryan Watts
Chief executive officer
US$7.9m
Total compensation
| CEO salary percentage | 8.5% |
| CEO tenure | 9.2yrs |
| CEO ownership | 1.6% |
| Management average tenure | 5.8yrs |
| Board average tenure | 8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$420m |
| Mar 31 2024 | n/a | n/a | -US$137m |
| Dec 31 2023 | US$8m | US$670k | -US$145m |
| Sep 30 2023 | n/a | n/a | -US$124m |
| Jun 30 2023 | n/a | n/a | -US$128m |
| Mar 31 2023 | n/a | n/a | -US$371m |
| Dec 31 2022 | US$9m | US$645k | -US$326m |
| Sep 30 2022 | n/a | n/a | -US$303m |
| Jun 30 2022 | n/a | n/a | -US$284m |
| Mar 31 2022 | n/a | n/a | -US$286m |
| Dec 31 2021 | US$13m | US$610k | -US$291m |
| Sep 30 2021 | n/a | n/a | US$30m |
| Jun 30 2021 | n/a | n/a | US$56m |
| Mar 31 2021 | n/a | n/a | US$58m |
| Dec 31 2020 | US$9m | US$589k | US$71m |
| Sep 30 2020 | n/a | n/a | -US$228m |
| Jun 30 2020 | n/a | n/a | -US$216m |
| Mar 31 2020 | n/a | n/a | -US$215m |
| Dec 31 2019 | US$5m | US$567k | -US$198m |
| Sep 30 2019 | n/a | n/a | -US$66m |
| Jun 30 2019 | n/a | n/a | -US$55m |
| Mar 31 2019 | n/a | n/a | -US$52m |
| Dec 31 2018 | US$6m | US$545k | -US$36m |
| Sep 30 2018 | n/a | n/a | -US$137m |
| Jun 30 2018 | n/a | n/a | -US$123m |
| Mar 31 2018 | n/a | n/a | -US$91m |
| Dec 31 2017 | US$1m | US$481k | -US$88m |
Compensation vs Market: Ryan's total compensation ($USD7.88M) is above average for companies of similar size in the BR market ($USD1.37M).
Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.
CEO
Ryan Watts (48 yo)
9.2yrs
Tenure
US$7,879,267
Compensation
Dr. Ryan J. Watts, Ph D., serves as Director at PEEL Therapeutics, Inc. since February 2023. He is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since Au...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.2yrs | US$7.88m | 1.57% R$ 350.8m | |
| Co-Founder | 9.6yrs | US$4.17m | 0.41% R$ 91.2m | |
| Co-Founder & Independent Director | no data | US$431.93k | 1.47% R$ 330.5m | |
| Chief Medical Officer & Head of Development | 9.3yrs | US$4.17m | 0.15% R$ 32.6m | |
| Senior Vice President of Corporate Finance | no data | no data | no data | |
| Chief Technical and Manufacturing Officer | 6.2yrs | no data | no data | |
| Chief Scientific Officer | 4.3yrs | no data | no data | |
| Vice President of Investor Relations | 4.8yrs | no data | no data | |
| General Counsel | 5.8yrs | no data | no data | |
| Vice President of Corporate Development | 1.8yrs | no data | no data | |
| Chief People Officer | no data | no data | no data | |
| Chief Commercial Officer | 3.1yrs | no data | no data |
5.8yrs
Average Tenure
51yo
Average Age
Experienced Management: D2NL34's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.6yrs | US$7.88m | 1.57% R$ 350.8m | |
| Co-Founder & Independent Director | 9.6yrs | US$431.93k | 1.47% R$ 330.5m | |
| Independent Chairperson | 9.5yrs | US$459.43k | 0.076% R$ 17.1m | |
| Independent Director | 9.5yrs | US$444.43k | 0.24% R$ 53.3m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 9.5yrs | US$439.43k | 0.051% R$ 11.4m | |
| Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
| Independent Director | 6.6yrs | US$439.43k | 0.011% R$ 2.4m | |
| Independent Director | 5.9yrs | US$429.43k | 0.0098% R$ 2.2m | |
| Director | 2.4yrs | US$419.43k | 0.58% R$ 129.5m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data |
8.0yrs
Average Tenure
64yo
Average Age
Experienced Board: D2NL34's board of directors are considered experienced (8 years average tenure).